Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a trial study assessing OKYO-0101 for dry eyes

Next Previous
Trial Profile

A Phase 1/2a trial study assessing OKYO-0101 for dry eyes

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Urcosimod (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 21 Feb 2023 According to Okyo media release, the company will also update on the recent filing of an investigational new drug (IND) application with FDA on OK-101 to treat DED.
  • 21 Feb 2023 According to Okyo media release, Dr. Alan Kopin, Chief Scientific Officer of On Target Therapeutics and the inventor of OK-101, will be presenting the research work that led to discovery of OK-101.
  • 21 Feb 2023 According to Okyo media release, the CEO of company will give an oral presentation entitled "A lapidated Protease-Resistant Chemerin Peptide Offers a Novel Therapeutic for Dry Eyes" on February 22, 2023 at the 2nd annual GPCRs-Targeted Drug Discovery Summit at the Hyatt Regency in Boston, MA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top